Circulating tumor DNA for predicting recurrence in patients with operable breast cancer : a systematic review and meta-analysis
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved..
BACKGROUND: The incorporation of circulating tumor DNA (ctDNA) into the management of operable breast cancer (BC) has been hampered by the heterogeneous results from different studies. We aimed to assess the prognostic value of ctDNA in patients with operable (non metastatic) BC.
MATERIALS AND METHODS: A systematic search of databases (PubMed/Medline, Embase, and CENTRAL) and conference proceedings was conducted to identify studies reporting the association of ctDNA detection with disease-free survival (DFS) and overall survival (OS) in patients with stage I-III BC. Log-hazard ratios (HRs) were pooled at each timepoint of ctDNA assessment (baseline, after neoadjuvant therapy, and follow-up). ctDNA assays were classified as primary tumor-informed and non tumor-informed.
RESULTS: Of the 3174 records identified, 57 studies including 5779 patients were eligible. In univariate analyses, ctDNA detection was associated with worse DFS at baseline [HR 2.98, 95% confidence interval (CI) 1.92-4.63], after neoadjuvant therapy (HR 7.69, 95% CI 4.83-12.24), and during follow-up (HR 14.04, 95% CI 7.55-26.11). Similarly, ctDNA detection at all timepoints was associated with worse OS (at baseline: HR 2.76, 95% CI 1.60-4.77; after neoadjuvant therapy: HR 2.72, 95% CI 1.44-5.14; and during follow-up: HR 9.19, 95% CI 3.26-25.90). Similar DFS and OS results were observed in multivariate analyses. Pooled HRs were numerically higher when ctDNA was detected at the end of neoadjuvant therapy or during follow-up and for primary tumor-informed assays. ctDNA detection sensitivity and specificity for BC recurrence ranged from 0.31 to 1.0 and 0.7 to 1.0, respectively. The mean lead time from ctDNA detection to overt recurrence was 10.81 months (range 0-58.9 months).
CONCLUSIONS: ctDNA detection was associated with worse DFS and OS in patients with operable BC, particularly when detected after treatment and using primary tumor-informed assays. ctDNA detection has a high specificity for anticipating BC relapse.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
ESMO open - 9(2024), 3 vom: 26. März, Seite 102390 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nader-Marta, G [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Breast neoplasms |
|---|
| Anmerkungen: |
Date Completed 27.03.2024 Date Revised 27.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.esmoop.2024.102390 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369499824 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369499824 | ||
| 003 | DE-627 | ||
| 005 | 20240328000104.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240310s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.esmoop.2024.102390 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1351.xml |
| 035 | |a (DE-627)NLM369499824 | ||
| 035 | |a (NLM)38460249 | ||
| 035 | |a (PII)S2059-7029(24)00158-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nader-Marta, G |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Circulating tumor DNA for predicting recurrence in patients with operable breast cancer |b a systematic review and meta-analysis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.03.2024 | ||
| 500 | |a Date Revised 27.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a BACKGROUND: The incorporation of circulating tumor DNA (ctDNA) into the management of operable breast cancer (BC) has been hampered by the heterogeneous results from different studies. We aimed to assess the prognostic value of ctDNA in patients with operable (non metastatic) BC | ||
| 520 | |a MATERIALS AND METHODS: A systematic search of databases (PubMed/Medline, Embase, and CENTRAL) and conference proceedings was conducted to identify studies reporting the association of ctDNA detection with disease-free survival (DFS) and overall survival (OS) in patients with stage I-III BC. Log-hazard ratios (HRs) were pooled at each timepoint of ctDNA assessment (baseline, after neoadjuvant therapy, and follow-up). ctDNA assays were classified as primary tumor-informed and non tumor-informed | ||
| 520 | |a RESULTS: Of the 3174 records identified, 57 studies including 5779 patients were eligible. In univariate analyses, ctDNA detection was associated with worse DFS at baseline [HR 2.98, 95% confidence interval (CI) 1.92-4.63], after neoadjuvant therapy (HR 7.69, 95% CI 4.83-12.24), and during follow-up (HR 14.04, 95% CI 7.55-26.11). Similarly, ctDNA detection at all timepoints was associated with worse OS (at baseline: HR 2.76, 95% CI 1.60-4.77; after neoadjuvant therapy: HR 2.72, 95% CI 1.44-5.14; and during follow-up: HR 9.19, 95% CI 3.26-25.90). Similar DFS and OS results were observed in multivariate analyses. Pooled HRs were numerically higher when ctDNA was detected at the end of neoadjuvant therapy or during follow-up and for primary tumor-informed assays. ctDNA detection sensitivity and specificity for BC recurrence ranged from 0.31 to 1.0 and 0.7 to 1.0, respectively. The mean lead time from ctDNA detection to overt recurrence was 10.81 months (range 0-58.9 months) | ||
| 520 | |a CONCLUSIONS: ctDNA detection was associated with worse DFS and OS in patients with operable BC, particularly when detected after treatment and using primary tumor-informed assays. ctDNA detection has a high specificity for anticipating BC relapse | ||
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a breast neoplasms | |
| 650 | 4 | |a circulating tumor DNA | |
| 650 | 4 | |a disease-free survival | |
| 650 | 4 | |a liquid biopsy | |
| 650 | 4 | |a prognosis | |
| 650 | 4 | |a sensitivity and specificity | |
| 650 | 4 | |a tumor biomarker | |
| 650 | 7 | |a Circulating Tumor DNA |2 NLM | |
| 700 | 1 | |a Monteforte, M |e verfasserin |4 aut | |
| 700 | 1 | |a Agostinetto, E |e verfasserin |4 aut | |
| 700 | 1 | |a Cinquini, M |e verfasserin |4 aut | |
| 700 | 1 | |a Martins-Branco, D |e verfasserin |4 aut | |
| 700 | 1 | |a Langouo, M |e verfasserin |4 aut | |
| 700 | 1 | |a Llombart-Cusac, A |e verfasserin |4 aut | |
| 700 | 1 | |a Cortés, J |e verfasserin |4 aut | |
| 700 | 1 | |a Ignatiadis, M |e verfasserin |4 aut | |
| 700 | 1 | |a Torri, V |e verfasserin |4 aut | |
| 700 | 1 | |a Apolone, G |e verfasserin |4 aut | |
| 700 | 1 | |a Cappelletti, V |e verfasserin |4 aut | |
| 700 | 1 | |a Pruneri, G |e verfasserin |4 aut | |
| 700 | 1 | |a de Azambuja, E |e verfasserin |4 aut | |
| 700 | 1 | |a Di Cosimo, S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ESMO open |d 2016 |g 9(2024), 3 vom: 26. März, Seite 102390 |w (DE-627)NLM266189539 |x 2059-7029 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2024 |g number:3 |g day:26 |g month:03 |g pages:102390 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.esmoop.2024.102390 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2024 |e 3 |b 26 |c 03 |h 102390 | ||